Ridgeline Therapeutics is developing drugs for the treatment of Type 2 diabetes, muscular dystrophy, and age-related muscle degeneration. The company is developing small molecule inhibitors of nicotinamide N-methyltransferase (NNMT). The enzyme is present in cytosols of adipocytes, hepatocytes, muscle, and responsible for regulating energy metabolism and epigenetic pathways. The company is in the drug discovery stage of development.

As at March 2025: We have developed a series of selective small molecule NNMT inhibitors with attractive drug-like properties, and are accelerating our efforts to transition our novel lead drug candidates through preclinical development and to Phase I trials.